MyCartis, a Switzerland and Belgium-based new company dedicated to changing healthcare through personalization originating from Biocartis’ business unit Evalution and Pronota, has launched Evalution, a multiplex biomarker analysis platform for the life sciences research market.
Evalution is MyCartis’ digital multiplex analysis platform tailored to clinical research and pharmaceutical markets and designed to analyze a broad range of protein and nucleic acid-based biomarkers, delivering high quality data and rapid results. Evalution provides an integrated reaction and detection environment and simultaneous analysis of large numbers of analytes per assay.
Biocartis is a global provider of personalized medicine and Pronota is a developer of diagnostics for early detection of life-threatening conditions and unmet medical needs. The combination of the Evalution platform, as designed by Biocartis, and Pronota’s portfolio of validated biomarkers will deliver state-of-the-art solutions for a range of diseases in the fields of cardiovascular and women's health.
"We believe that every individual has the right to good health. But we know that the current health model of ‘one size fits all’ is unsustainable," said Paul Ladestein, CEO of MyCartis. “By developing biomarker analysis solutions at the forefront of innovation we want to improve healthcare worldwide. Our next generation multiplexing platform Evalution will support researchers to better understand the role of biomarkers in early disease and risk diagnosis and patient management. Evalution can analyze an individual’s protein and molecular profile in a single assay plate.”
MyCartis also engages in licensing opportunities with companies aiming to develop their own commercial applications on the Evalution platform. Furthermore, MyCartis develops and validates novel applications with simpler assay formats and unique biomarkers for a range of diseases.